Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Budget Issues Creep Into Strategic Priorities

This article was originally published in The Pink Sheet Daily

Executive Summary

“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.

Advertisement

Related Content

FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level
Pharmaceutical Quality And Generic Drugs: Janet Woodcock Explains Her Vision
Should FDA Be Forced To Consider Development Time And Cost?
FDA Outlines Priorities For Next Five Years In Strategic Report

Topics

Advertisement
UsernamePublicRestriction

Register

PS077458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel